Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer, effective immediately. Dr. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will now oversee scientific strategy and research operations across Annovis’ Alzheimer’s disease and Parkinson’s disease programs. His responsibilities will include translational science, clinical development, biomarker strategy and regulatory interactions.
The promotion comes at a critical time for Annovis as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application submission. The company stated that Dr. Fang has played a key role in advancing its clinical development efforts and will lead its scientific strategy through upcoming clinical and regulatory milestones.
Buntanetap (formerly posiphen) is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
Annovis Bio is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, developing treatments for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. For more information, visit www.annovisbio.com.
The full press release is available at https://ibn.fm/c9jdt.
